CRL vs PATH · rev $4.05B vs P/E 19, rev $1.61B
Charles River Laboratories (CRL) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported CRL revenue for 2024-12-28 was $4.05B. Net income was $25.3M. Revenue was down 1.9% from 2023-12-30 to 2024-12-28. CRL currently screens at market cap $7.78B.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
CRL currently screens at market cap $7.78B. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the CRL and PATH stock pages for the full models.
Not investment advice.